

Optum Specialty Phone: 855-427-4682 Optum Specialty Fax: 877-342-4596

Osteoporosis Enrollment Form

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy - tear here.

This form is not a valid prescription in Arizona or Virginia

PATIENT INFORMATION			PRESCRIBER INFORMATION			
Please complete the following or send patient demographic sheet			Prescriber's Name			
Patient Name			DEA			
Address			NPI			
Address 2			Group/Hospital			
City, State, ZIP			Address			
Home Phone Alternate Phone			City, State, ZIP			
DOB Last Four of SS# Gender Language Preference: English Spanish Other						
	-				Phone	
INSURANCE INFORMATI	$oxed{ON}$ (Must fax a copy of patient's i	insurance ca	ard including both sides)			
Prior Authorization Reference number _						
MEDICAL INFORMATION	N (Section must be comp	oleted to	process prescription)	(Attach separat	e sheet if needed))
Diagnosis – Please include diagnosis nan	ne with ICD-10 code		Additional Information Th	erapy: New	Reauthorization	Restart
ICD-10 Description _			Weightkg/lbs	Height	cm/in BSA	m ²
Disease State Description:			Allergies			
Postmenopausal osteoporosis with high fracture risk (female)			Fracture History			
	, ,		Tractare mistory			
Postmenopausal osteoporosis prophylaxis			Prior Failed Therapies:			
Hypogonadal osteoporosis with high fracture risk (male)						
Glucocorticoid-induced osteoporosis treatment/prophylaxis			Actonel® (risedronate) Boniva® (ibandronate)			
Paget's disease			Fosamax® (alendronate) Prolia® (denosumab)			
Other:			Reclast® (Zoledronic Acid Injection)			
Date of Diagnosis			Concomitant Medications			
Test Results:	W	NL:				
Serum calcium Yes No			Additional Comments			
SCr/CrCI	Yes	No				
BMD Yes No			Treatment Start Date Treatment End Date			
T score Yes No						
PRESCRIPTION INFORM Medication	Dose/Strength	ı	Directions		Quantity	Refills
	Dose/ Strength		Directions		Quantity	Remis
Evenity® (romosozumab-aqqg)						
Forteo®		·				+
(teriparatide, recombinant)						
Prolia® (denosumab)						
Reclast® (zoledronic acid)		1				
┌┐ Tymlos®		1				1
└ (ábaloparatide)						
	•					•
Ship to: Office Other *Prescriber Authorization: I authorize this pharmacy and its representat	ives to act as my authorized agent including but not limited to	attestations of mo-	Date		eeded	necessary forms where
permitted by law and benefit plan sponsor, on my behalf as my authorize fulfill this prescription, I further authorize this pharmacy to forward this	ed agent, including any required prior authorization forms and t	he receipt and subn	nission of patient lab values and other patient data that supp	ort the prior authorization. In t		
Dispense	e as Written			Substitution pern	nitted	
Prescriber's Signature Date			Prescriber's Signature Date			
Electronic or digital signatures not accepted		_				

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.